Looking Back on 2018: Our 10 Most Popular Interviews
As 2018 draws to a close and our thoughts are torn between holiday plans and…
As 2018 draws to a close and our thoughts are torn between holiday plans and…
A new CAR-T cancer therapy from the Belgian company Celyad has shown early positive results…
Update: Following on from earlier approvals in the US, the European Commission announced it has given…
Sangamo Therapeutics has acquired TxCell with a view to utilizing its CAR-T technology to prevent…
Kite will support Gadeta in the development of a new type of CAR-T therapy that…
London-based Autolus has made its debut on the NASDAQ raising funds to boost the development of a…
Cellectis is developing a new type of chimeric antigen receptor that could improve the production…
CAR-T cell therapy has been able to effectively treat cancer in some patients for whom…
Update (23/05/2018): Investors have fully subscribed Celyad's global offering of shares on NASDAQ and Euronext…
TC Biopharm has partnered with Scotia Biologics to produce tumor-specific antibodies for a new generation…
The FDA has approved the use of Novartis' CAR-T therapy Kymriah in adult patients with…
Novartis' Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in…